237 related articles for article (PubMed ID: 28821635)
1. Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.
Majtan T; Hůlková H; Park I; Krijt J; Kožich V; Bublil EM; Kraus JP
FASEB J; 2017 Dec; 31(12):5495-5506. PubMed ID: 28821635
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement with PEGylated cystathionine β-synthase ameliorates homocystinuria in murine model.
Bublil EM; Majtan T; Park I; Carrillo RS; Hůlková H; Krijt J; Kožich V; Kraus JP
J Clin Invest; 2016 Jun; 126(6):2372-84. PubMed ID: 27183385
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of PEGylated truncated human cystathionine beta-synthase for treatment of homocystinuria.
Majtan T; Bublil EM; Park I; Arning E; Bottiglieri T; Glavin F; Kraus JP
Life Sci; 2018 May; 200():15-25. PubMed ID: 29526799
[TBL] [Abstract][Full Text] [Related]
4. Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy.
Majtan T; Park I; Cox A; Branchford BR; di Paola J; Bublil EM; Kraus JP
FASEB J; 2019 Nov; 33(11):12477-12486. PubMed ID: 31450979
[TBL] [Abstract][Full Text] [Related]
5. Long-term uninterrupted enzyme replacement therapy prevents liver disease in murine model of severe homocystinuria.
Park I; Hůlková H; Krijt J; Kožich V; Bublil EM; Majtan T
Hum Mutat; 2020 Sep; 41(9):1662-1670. PubMed ID: 32623804
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy prevents loss of bone and fat mass in murine homocystinuria.
Majtan T; Park I; Bublil EM; Kraus JP
Hum Mutat; 2018 Feb; 39(2):210-218. PubMed ID: 29044829
[TBL] [Abstract][Full Text] [Related]
7. Derangement of hepatic polyamine, folate, and methionine cycle metabolism in cystathionine beta-synthase-deficient homocystinuria in the presence and absence of treatment: Possible implications for pathogenesis.
Maclean KN; Jiang H; Phinney WN; Mclagan BM; Roede JR; Stabler SP
Mol Genet Metab; 2021 Feb; 132(2):128-138. PubMed ID: 33483253
[TBL] [Abstract][Full Text] [Related]
8. Taurine treatment prevents derangement of the hepatic γ-glutamyl cycle and methylglyoxal metabolism in a mouse model of classical homocystinuria: regulatory crosstalk between thiol and sulfinic acid metabolism.
Maclean KN; Jiang H; Aivazidis S; Kim E; Shearn CT; Harris PS; Petersen DR; Allen RH; Stabler SP; Roede JR
FASEB J; 2018 Mar; 32(3):1265-1280. PubMed ID: 29101223
[TBL] [Abstract][Full Text] [Related]
9. Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria.
Majtan T; Jones W; Krijt J; Park I; Kruger WD; Kožich V; Bassnett S; Bublil EM; Kraus JP
Mol Ther; 2018 Mar; 26(3):834-844. PubMed ID: 29398487
[TBL] [Abstract][Full Text] [Related]
10. Taurine alleviates repression of betaine-homocysteine
Maclean KN; Jiang H; Phinney WN; Keating AK; Hurt KJ; Stabler SP
FASEB J; 2019 May; 33(5):6339-6353. PubMed ID: 30768359
[TBL] [Abstract][Full Text] [Related]
11. Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model.
Wang L; Chen X; Tang B; Hua X; Klein-Szanto A; Kruger WD
Hum Mol Genet; 2005 Aug; 14(15):2201-8. PubMed ID: 15972722
[TBL] [Abstract][Full Text] [Related]
12. Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies.
Bublil EM; Majtan T
Biochimie; 2020 Jun; 173():48-56. PubMed ID: 31857119
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: possible implications for cardiovascular outcomes.
Jiang H; Stabler SP; Allen RH; Maclean KN
Mol Genet Metab; 2012 Sep; 107(1-2):55-65. PubMed ID: 22633282
[TBL] [Abstract][Full Text] [Related]
14. A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment.
Maclean KN; Sikora J; Kožich V; Jiang H; Greiner LS; Kraus E; Krijt J; Overdier KH; Collard R; Brodsky GL; Meltesen L; Crnic LS; Allen RH; Stabler SP; Elleder M; Rozen R; Patterson D; Kraus JP
Mol Genet Metab; 2010; 101(2-3):153-62. PubMed ID: 20638879
[TBL] [Abstract][Full Text] [Related]
15. Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver.
Robert K; Nehmé J; Bourdon E; Pivert G; Friguet B; Delcayre C; Delabar JM; Janel N
Gastroenterology; 2005 May; 128(5):1405-15. PubMed ID: 15887121
[TBL] [Abstract][Full Text] [Related]
16. Betaine supplementation is less effective than methionine restriction in correcting phenotypes of CBS deficient mice.
Gupta S; Wang L; Kruger WD
J Inherit Metab Dis; 2016 Jan; 39(1):39-46. PubMed ID: 26231230
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Cystathionine β-Synthase Deficiency in Mice Using a Minicircle-Based Naked DNA Vector.
Lee HO; Gallego-Villar L; Grisch-Chan HM; Häberle J; Thöny B; Kruger WD
Hum Gene Ther; 2019 Sep; 30(9):1093-1100. PubMed ID: 31084364
[TBL] [Abstract][Full Text] [Related]
18. Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.
Gupta S; Wang L; Anderl J; Slifker MJ; Kirk C; Kruger WD
Hum Mutat; 2013 Aug; 34(8):1085-93. PubMed ID: 23592311
[TBL] [Abstract][Full Text] [Related]
19. Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria.
Park ES; Oh HJ; Kruger WD; Jung SC; Lee JS
Exp Mol Med; 2006 Dec; 38(6):652-61. PubMed ID: 17202841
[TBL] [Abstract][Full Text] [Related]
20. Engineering and Characterization of an Enzyme Replacement Therapy for Classical Homocystinuria.
Majtan T; Park I; Carrillo RS; Bublil EM; Kraus JP
Biomacromolecules; 2017 Jun; 18(6):1747-1761. PubMed ID: 28431470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
